Pfizer and Acura receive US FDA approval for Oxecta immediate-release pain killer Print E-mail
By Deborah Sterescu -   
Monday, 20 June 2011 22:51
Pfizer (NYSE:PFE) and Acura Pharmaceuticals (NASDAQ:ACUR) said Monday that the US FDA has approved their Oxecta pain killer drug for marketing.

Oxecta is the first immediate-release form of oxycodone HCl medicine, which applies technology designed to discourage common methods of tampering associated with opioid, or opium, abuse and misuse.

This aversion technology is a unique combination of commonly used pharmaceutical ingredients, which was licensed by Pfizer from Acura.

Opioid medications are an important treatment option for patients with moderate to severe pain, who do not respond well to other treatments. However, abuse and misuse is a common problem.

"We recognize our responsibility to physicians and patients and remain committed to appropriate access to pain treatment and developing medicines to potentially address this important public health and safety issue," said president and general manager of Pfizer Primary Care, Olivier Brandicourt.

"OXECTA will further expand Pfizer's presence in pain management and complements our growing, robust portfolio of treatments and medicines in development for pain relief, one of our strategic, high-priority disease areas."

The most common adverse reactions of the drug are nausea, constipation, vomiting, headache, itchiness, trouble sleeping, dizziness, loss of strength/energy, and sleepiness.

Acura is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to potentially deter abuse and misuse using its Aversion and Impede technologies. The company's shares rose more than 16% on Monday afternoon to trade at $4.50.

Proactiveinvestors is a leading news organisation and event business with offices in New York, Sydney, Toronto and London. The Company is a publisher and is not registered with the US Securities Exchange Commission or Ontario Securities Commission. Please read our full terms and conditions here 

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus